TY - JOUR
T1 - Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines
AU - Wierda, William G.
AU - Brown, Jennifer
AU - Abramson, Jeremy S.
AU - Awan, Farrukh
AU - Bilgrami, Syed F.
AU - Bociek, Greg
AU - Brander, Danielle
AU - Chanan-Khan, Asher A.
AU - Coutre, Steve E.
AU - Davis, Randall S.
AU - Eradat, Herbert
AU - Fletcher, Christopher D.
AU - Gaballa, Sameh
AU - Ghobadi, Armin
AU - Saad Hamid, Muhammad
AU - Hernandez-Ilizaliturri, Francisco
AU - Hill, Brian
AU - Kaesberg, Paul
AU - Kamdar, Manali
AU - Kaplan, Lawrence D.
AU - Khan, Nadia
AU - Kipps, Thomas J.
AU - Ma, Shuo
AU - Mato, Anthony
AU - Mosse, Claudio
AU - Schuster, Stephen
AU - Siddiqi, Tanya
AU - Stephens, Deborah M.
AU - Ujjani, Chaitra
AU - Wagner-Johnston, Nina
AU - Woyach, Jennifer A.
AU - Ye, J. Christine
AU - Dwyer, Mary A.
AU - Sundar, Hema
N1 - Funding Information:
This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm® Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc.
Funding Information:
William G. Wierda, MD, PhD, Panel Chair, grant/research support from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Cyclacel Pharmaceuticals, Inc., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceutica Products, LP, Juno Therapeutics, Inc., Kite Pharma, Miragen Therapeutics, Inc., Oncternal Therapeutics, Inc., Pharmacyclics, Sunesis Pharmaceuticals, Inc., and Xencor, Inc. Jennifer Brown, MD, PhD, Panel Vice Chair, consulting fees from AbbVie, Inc./Roche Laboratories, Inc., Acerta Pharma/AstraZeneca Pharmaceuticals LP, BeiGene/ AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company/Celgene Corporation/Juno Therapeutics, Catapult Therapeutics, Eli Lilly and Company, Genentech, Inc./Roche Laboratories, Inc., Janssen Pharmaceutica, Products, LP., MEI Pharma Inc., MorphoSys AG, Nextcea, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Rigel Pharmaceuticals, Inc.; grant/research support from Gilead Sciences Inc., Loxo Oncology at Lilly, Secura Bio, Inc., Sun Pharma, and TG Therapeutics, Inc.; and scientific advisor for Invectys.
Publisher Copyright:
© 2022 Harborside Press. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
AB - The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
UR - http://www.scopus.com/inward/record.url?scp=85132455187&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2022.0031
DO - 10.6004/jnccn.2022.0031
M3 - Article
C2 - 35714675
AN - SCOPUS:85132455187
SN - 1540-1405
VL - 20
SP - 622
EP - 634
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 6
ER -